AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30875151 — intervention group
Group type: COMPARATOR
Intervention: Probiotic cake and Regular cake
Number of subjects: 40
Study 28282381 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA blood test at a threshold of 5μg/L
Number of subjects: 582
Study 28282381 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA blood test at a threshold of 2.5μg/L
Number of subjects: 582
Study 25427243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of human umbilical cord mesenchymal stem cells (low-dose 3x10^6, mid-dose 4x10^6, high-dose 5x10^6)
Number of subjects: 15
Study 23735408 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-monitoring with self-titration of antihypertensives
Number of subjects: 16
Study 22099892 — intervention group
Group type: EXPERIMENTAL
Intervention: NEC for 2 weeks
Number of subjects: 32
Study 22099892 — intervention group
Group type: EXPERIMENTAL
Intervention: NEC for 8 weeks
Number of subjects: 32
Study 22099892 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA for 2 weeks
Number of subjects: 32
Study 22099892 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA for 8 weeks
Number of subjects: 32
Study 18584303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (I) participated in focus group and role play at 2 and 4 months after recruitment.
Number of subjects: 292
Study 18584303 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) received oral information.
Number of subjects: 292
Study 16978740 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial submissions of RCTs
Number of subjects: 62
Study 16978740 — intervention group
Group type: EXPERIMENTAL
Intervention: Published articles
Number of subjects: 62
Study 16978740 — intervention group
Group type: COMPARATOR
Intervention: BMJ external peer review process
Number of subjects: 62
Study 15584811 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience-based JOLs
Number of subjects: 0
Study 15584811 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based JOLs
Number of subjects: 0
Study 15584811 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated retention interval
Number of subjects: 0
Study 12536592 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin suppository
Number of subjects: 80
Study 12536592 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole suppository
Number of subjects: 80
Study 9426669 — intervention group
Group type: EXPERIMENTAL
Intervention: External ultrasonic tumescent liposuction (10 minutes of preoperative ultrasound therapy)
Number of subjects: 10
Study 9426669 — intervention group
Group type: EXPERIMENTAL
Intervention: External ultrasonic tumescent liposuction
Number of subjects: 10
Study 8275064 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity cognitive-behavioral group psychotherapy
Number of subjects: 0
Study 8275064 — intervention group
Group type: EXPERIMENTAL
Intervention: Early abstinence cognitive-behavioral group psychotherapy
Number of subjects: 0
Study 8275064 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of high intensity and early abstinence cognitive-behavioral group psychotherapy
Number of subjects: 0
Study 8275064 — intervention group
Group type: COMPARATOR
Intervention: Weekly psychotherapy using manual-based cognitive-behavioral therapy
Number of subjects: 0
Study 2872874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 96
Study 2872874 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 96
Study 2872874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 2872874 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible vessel group
Number of subjects: 96
Study 2872874 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery group (visible vessel)
Number of subjects: 96
Study 2872874 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative measures group (visible vessel)
Number of subjects: 96
Study 30566007 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 2000 mg daily for 3 months
Number of subjects: 48
Study 30566007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 28479901 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 12 weeks
Number of subjects: 80
Study 28479901 — intervention group
Group type: COMPARATOR
Intervention: No exercise training for 12 weeks
Number of subjects: 80
Study 25131356 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine hydrochloride 2μgkg(‐1)min(‐1)
Number of subjects: 124
Study 25131356 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine hydrochloride 4μgkg(‐1)min(‐1)
Number of subjects: 124
Study 25131356 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine hydrochloride 6μgkg(‐1)min(‐1)
Number of subjects: 124
Study 25131356 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline infusion)
Number of subjects: 124
Study 23006861 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 20-min sessions/wk
Number of subjects: 60
Study 23006861 — intervention group
Group type: EXPERIMENTAL
Intervention: One 20-min session/wk
Number of subjects: 60
Study 23006861 — intervention group
Group type: COMPARATOR
Intervention: No balance training (control)
Number of subjects: 60
Study 21199787 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg magnesium/day as magnesium citrate
Number of subjects: 100
Study 21199787 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium citrate)
Number of subjects: 100
Study 18793926 — intervention group
Group type: EXPERIMENTAL
Intervention: White mineral trioxide aggregate (MTA) used as a root‐end filling material exposed to pH 4.4 for 3 days
Number of subjects: 70
Study 18793926 — intervention group
Group type: EXPERIMENTAL
Intervention: White mineral trioxide aggregate (MTA) used as a root‐end filling material exposed to pH 5.4 for 3 days
Number of subjects: 70
Study 18793926 — intervention group
Group type: EXPERIMENTAL
Intervention: White mineral trioxide aggregate (MTA) used as a root‐end filling material exposed to pH 6.4 for 3 days
Number of subjects: 70
Study 18793926 — intervention group
Group type: EXPERIMENTAL
Intervention: White mineral trioxide aggregate (MTA) used as a root‐end filling material exposed to pH 7.4 for 3 days
Number of subjects: 70
Study 18793926 — intervention group
Group type: COMPARATOR
Intervention: Control group (root‐end cavities not filled)
Number of subjects: 70
Study 11431298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry-lingonberry juice (50 ml daily for six months)
Number of subjects: 150
Study 11431298 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG drink (100 ml five days a week for one year)
Number of subjects: 150
Study 11431298 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 150
Study 9923579 — intervention group
Group type: EXPERIMENTAL
Intervention: PcV (conventional phenoxymethylpenicillin tablet)
Number of subjects: 24
Study 9923579 — intervention group
Group type: COMPARATOR
Intervention: PcVsr (saliva-resistant coated tablet)
Number of subjects: 24
Study 9923579 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (PcV and PcVsr)
Number of subjects: 24
Study 9923579 — intervention group
Group type: EXPERIMENTAL
Intervention: PcVsr
Number of subjects: 24
Study 9923579 — intervention group
Group type: COMPARATOR
Intervention: PcV
Number of subjects: 24
Study 8155443 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 26
Study 8155443 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 26
Study 3075601 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (40 mg/day)
Number of subjects: 95
Study 3075601 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg/day)
Number of subjects: 95
Study 3075601 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (40 mg) during acute oral test
Number of subjects: 95
Study 3075601 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg) during acute oral test
Number of subjects: 95
Study 3075601 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 95
Study 31419349 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BCC genetic risk score
Number of subjects: 604
Study 30482494 — intervention group
Group type: EXPERIMENTAL
Intervention: Major ventricular arrhythmias (VAs) developed in 105 patients (5.1%).
Number of subjects: 2074
Study 30482494 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of depression present in 22.2% of patients at baseline, declined to 14.1% at 1 month post-discharge.
Number of subjects: 2074
Study 30482494 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of anxiety present in 23.5% of patients at baseline, declined to 12.6% at 1 month post-discharge.
Number of subjects: 2074
Study 30482494 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-2 and GAD-2 scores were used to measure symptoms at 3, 6, and 12 months.
Number of subjects: 2074
Study 28339847 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise advice in addition to existing care (5-10 calls over 6 months from a physical therapist trained in behavior change support)
Number of subjects: 175
Study 28339847 — intervention group
Group type: COMPARATOR
Intervention: Existing care (minimum of one phone call from a nurse for advice on OA self-management)
Number of subjects: 175
Study 28339847 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise advice in addition to existing care
Number of subjects: 175
Study 28339847 — intervention group
Group type: COMPARATOR
Intervention: Existing care
Number of subjects: 175
Study 25365531 — intervention group
Group type: EXPERIMENTAL
Intervention: Veracity test method
Number of subjects: 0
Study 25365531 — intervention group
Group type: COMPARATOR
Intervention: Behavioral indicator recognition
Number of subjects: 0
Study 23885659 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple antenatal contraceptive counselling sessions
Number of subjects: 216
Study 23885659 — intervention group
Group type: COMPARATOR
Intervention: Single postnatal counselling session
Number of subjects: 216
Study 23885659 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal group (previously undecided patients)
Number of subjects: 216
Study 21554920 — intervention group
Group type: EXPERIMENTAL
Intervention: Artglass composite resin inlays
Number of subjects: 89
Study 21554920 — intervention group
Group type: EXPERIMENTAL
Intervention: Charisma composite resin inlays
Number of subjects: 89
Study 21554920 — intervention group
Group type: COMPARATOR
Intervention: Both inlay systems
Number of subjects: 89
Study 17416370 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 0
Study 17416370 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg/day
Number of subjects: 0
Study 17416370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16866581 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Stroop task
Number of subjects: 152
Study 16866581 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition task
Number of subjects: 152
Study 16866581 — intervention group
Group type: COMPARATOR
Intervention: Dot-probe task
Number of subjects: 152
Study 12700295 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy
Number of subjects: 20
Study 12700295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10828926 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 100
Study 10828926 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 100
Study 10828926 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed surgery after conservative treatment
Number of subjects: 100
Study 10828926 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized surgical treatment
Number of subjects: 100
Study 10828926 — intervention group
Group type: COMPARATOR
Intervention: Randomized conservative treatment
Number of subjects: 100
Study 9322620 — intervention group
Group type: EXPERIMENTAL
Intervention: Active electrical device
Number of subjects: 121
Study 9322620 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 121
Study 8223847 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25-50 mg o.d. (n = 116)
Number of subjects: 250
Study 8223847 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25-50 mg o.d. (n = 117)
Number of subjects: 250
Study 8223847 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 250
Study 8223847 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 250
Study 31599919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone monoester drink (0.45 mL/kg body weight)
Number of subjects: 15
Study 31599919 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone monoester drink
Number of subjects: 15
Study 28830293 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated treatment plan (mean doses up to 95 Gy/33 fractions for tumor and 74 Gy/33 fractions for lymph nodes)
Number of subjects: 27
Study 28830293 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment plan
Number of subjects: 27
Study 26708778 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled TMS (SCH)
Number of subjects: 49
Study 26708778 — intervention group
Group type: COMPARATOR
Intervention: Observation only (OBS)
Number of subjects: 49
Study 26708778 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study completion
Number of subjects: 49
Study 25183043 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing-based, individualized counseling and referral intervention for physical activity promotion
Number of subjects: 340
Study 22298571 — intervention group
Group type: EXPERIMENTAL
Intervention: UNIMMAP (prenatal multiple micronutrients)
Number of subjects: 1056
Study 22298571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative Micronutrient Intake (CMI)
Number of subjects: 1056
Study 22298571 — intervention group
Group type: COMPARATOR
Intervention: UNIMMAP and IFA
Number of subjects: 1056
Study 20298571 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MM) with vitamin A
Number of subjects: 393
Study 20298571 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A plus zinc (VAZ)
Number of subjects: 393
Study 20298571 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A (VA)
Number of subjects: 393
Study 18204338 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily
Number of subjects: 311
Study 18204338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 16313986 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 20
Study 16313986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 14656612 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 2457
Study 14656612 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive strategy
Number of subjects: 2457
Study 14656612 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive strategy with revascularization
Number of subjects: 2457
Study 14656612 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive strategy without revascularization
Number of subjects: 2457
Study 11035617 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed cohort analysis
Number of subjects: 0
Study 11035617 — intervention group
Group type: EXPERIMENTAL
Intervention: Open cohort analysis
Number of subjects: 0
Study 11035617 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up
Number of subjects: 0
Study 8977599 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms twice daily
Number of subjects: 16
Study 8977599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1600052 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 10 mg
Number of subjects: 36
Study 1600052 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 20 mg
Number of subjects: 36
Study 1600052 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg
Number of subjects: 36
Study 1600052 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg (morning dosing)
Number of subjects: 36
Study 1600052 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg (evening dosing)
Number of subjects: 36
Study 1600052 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (all doses)
Number of subjects: 36
Study 1600052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3917659 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 33
Study 3917659 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 33
Study 30650997 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1 (decision tree)
Number of subjects: 55
Study 30650997 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2 (random forest)
Number of subjects: 55
Study 30074294 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily
Number of subjects: 502
Study 30074294 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone (SFC) 50/500 μg twice daily
Number of subjects: 502
Study 26946619 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) applied with direct current (DC) on acupoints Pucan (BL 61) and Shenmai (BL 62) for 20 min.
Number of subjects: 82
Study 26946619 — intervention group
Group type: COMPARATOR
Intervention: Control group received no TENS electrode treatments.
Number of subjects: 82
Study 24448103 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day
Number of subjects: 426
Study 24448103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study 22266414 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0
Study 22266414 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 0
Study 22266414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20586527 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-hemispheric deep brain stimulation (DBS)
Number of subjects: 12
Study 17846391 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (ergocalciferol or cholecalciferol) with daily doses varying from 300 to 2000 IU, mean daily dose of 528 IU.
Number of subjects: 57311
Study 17846391 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplements (added in some trials).
Number of subjects: 57311
Study 17846391 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or no vitamin D supplementation).
Number of subjects: 57311
Study 16355950 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% apraclonidine hydrochloride
Number of subjects: 75
Study 16355950 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide hydrochloride
Number of subjects: 75
Study 16355950 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (control)
Number of subjects: 75
Study 11942445 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visits to practices that received two of four guidelines.
Number of subjects: 70
Study 11942445 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visits to smaller practices (two or fewer full-time equivalent practitioners).
Number of subjects: 70
Study 11942445 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visits to larger practices.
Number of subjects: 70
Study 9476875 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (500 microg via small-volume metal spacer)
Number of subjects: 22
Study 9476875 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 22
Study 7637478 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin once daily (n = 176)
Number of subjects: 339
Study 7637478 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control group, n = 163)
Number of subjects: 339
Study 2795725 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin 50 mg at bedtime for the first 2 weeks, increased by 25 mg in the morning for the last week of a 3-week treatment period.
Number of subjects: 19
Study 2795725 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin treatment
Number of subjects: 19
Study 319356 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide, 10 mg four times daily
Number of subjects: 31
Study 319356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 30628860 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth device for in-home use
Number of subjects: 24
Study 30628860 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 24
Study 27821374 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloon (PTX-B)
Number of subjects: 223
Study 27821374 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 223
Study 25988935 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐ATG/EVR (n = 85)
Number of subjects: 288
Study 25988935 — intervention group
Group type: EXPERIMENTAL
Intervention: BAS/EVR (n = 102)
Number of subjects: 288
Study 25988935 — intervention group
Group type: COMPARATOR
Intervention: BAS/MPS (n = 101)
Number of subjects: 288
Study 23234725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (DF) treatment for chronic hepatitis B infection for at least 5 years
Number of subjects: 641
Study 21623240 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based collaborative care
Number of subjects: 395
Study 21623240 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 395
Study 19460254 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug fixed-dose combination (4-FDC) regimen
Number of subjects: 1159
Study 19460254 — intervention group
Group type: COMPARATOR
Intervention: Single tablet regimen (ST)
Number of subjects: 1159
Study 16678649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts extended release (MAS XR) 10, 20, and 30 mg/d
Number of subjects: 57
Study 16678649 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine 0.5 and 1.2 mg/kg per day
Number of subjects: 57